Lofexidine is a selective α2-receptor agonist, Lofexidine reduces narcotic withdrawal symptoms.

8-day, randomized, double-blind, placebo-controlled, parallel-group study in 264 patients dependent on short-acting opioids evaluated the efficacy of lofexidine hydrochloride in reducing withdrawal symptoms in patients undergoing opioid withdrawal.?The primary efficacy measures were SOWS-Gossop on Day 3 and time-to-dropout.?Secondary endpoints included the proportion of participants who were completers;?area under the 5-day SOWS-Gossop - time curve (i.e., AUC1-5), and daily mean SOWS-Gossop, OOWS-Handelsman, MCGI (subject and rater), and VAS-E scores.?Participants received lofexidine HCl 3.2mg daily in four divided doses or matching placebo on Days 1-5, followed by 2days of placebo[1].